Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Venetoclax in Higher-risk Chronic Myelomonocytic Leukemia
NCT05768711Phase 2Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Safety run-in at 8 weeks and Overall response rate at 24 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05768711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768711.